Stockscreener 앱 받기
1.39
0.72%
0.01
시간 외 거래:
1.33
-0.06
-4.32%
전일 마감가:
$1.38
열려 있는:
$1.36
하루 거래량:
912.23K
Relative Volume:
0.43
시가총액:
$66.66M
수익:
-
순이익/손실:
$-97.22M
주가수익비율:
-1.0072
EPS:
-1.38
순현금흐름:
$-82.44M
1주 성능:
-20.57%
1개월 성능:
-42.08%
6개월 성능:
-94.84%
1년 성능:
-92.95%
1일 변동 폭
$1.3405
$1.4198
1주일 범위
$1.3405
$1.79
52주 변동 폭
$1.3405
$42.20
카사바 Stock (SAVA) Company Profile
명칭
Cassava Sciences Inc
전화
512-501-2444
주소
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
SAVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
1.39 | 66.66M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
카사바 Stock (SAVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-27 | 개시 | B. Riley Securities | Buy |
| 2021-02-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-01-10 | 재확인 | Maxim Group | Buy |
모두보기
카사바 주식(SAVA)의 최신 뉴스
SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance
After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient
Is the Future Bleak for SAVA Stock Following Another Setback? - Yahoo Finance
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN
Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research
Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter
Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance
Rodman & Renshaw maintains Sell rating on Cassava Sciences stock By Investing.com - Investing.com South Africa
SAVA stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Sector Update: Health Care Stocks Fall Late Afternoon - TradingView
Sector Update: Health Care - MarketScreener
Rodman & Renshaw maintains Sell rating on Cassava Sciences stock - Investing.com India
Top Midday Decliners - MarketScreener
Cassava Sciences Stock: Alzheimer Drug Fails, Program Terminated - Sharewise
Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program - Yahoo Finance
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam - BioSpace
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop - Benzinga
Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kaken - Endpoints News
Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study - NewsBreak: Local News & Alerts
Cassava stock down as Alzheimer’s program ends (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences shuts down Alzheimer's programshares plummet - Marketscreener.com
SAVA stock touches 52-week low at $2.15 amid market challenges - Investing.com Australia
Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients - MarketScreener
Cassava to discontinue development of Alzheimer’s disease drug - KFGO
Cassava Sciences ends Alzheimer’s treatment development after unsuccessful trials By Investing.com - Investing.com UK
Cassava Sciences stock tumbles after Alzheimer’s drug fails key study By Investing.com - Investing.com Canada
Cassava to discontinue development of Alzheimer's disease drug - Marketscreener.com
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data - GlobeNewswire
Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data - MarketScreener
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAVA - ACCESS Newswire
Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments - Seeking Alpha
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Cassava Sciences revises executive bonus plan By Investing.com - Investing.com South Africa
SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava S - GuruFocus.com
Cassava Sciences Amends Bonus Plan After Court Settlement - TipRanks
Cassava Sciences revises executive bonus plan - Investing.com
카사바 (SAVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):